Iron dosing in kidney disease: Inconsistency of evidence and clinical practice

Nephrology Dialysis Transplantation

Volumn 30, Issue 2, 2015, Pages 187-196

  Gaweda, Adam E ^a   Ginzburg, Yelena Z ^b   Chait, Yossi ^c   Germain, Michael J ^d   Aronoff, George R ^a   Rachmilewitz, Eliezer ^e  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b NEW YORK BLOOD CENTER   (United States)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WOLFSON MEDICAL CENTER   (Israel)

Author keywords

anemia; erythropoiesis; iron; iron deficiency; iron overload; kidney disease

Indexed keywords

ANTIANEMIC AGENT; CD71 ANTIGEN; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; IRON; TRANSFERRIN; IRON DERIVATIVE;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; END STAGE RENAL DISEASE; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY; IRON OVERLOAD; IRON STORAGE; IRON THERAPY; KIDNEY DISEASE; KIDNEY FAILURE; MAINTENANCE DRUG DOSE; REVIEW; ANEMIA, IRON-DEFICIENCY; CHRONIC KIDNEY FAILURE; COMPLICATION;

ANEMIA, IRON-DEFICIENCY; ERYTHROPOIETIN; HEMATINICS; HUMANS; IRON COMPOUNDS; IRON OVERLOAD; RENAL INSUFFICIENCY, CHRONIC;

EID: 84922542101     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu104     Document Type: Review

References (113)

1. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
2. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
3. PfefferMA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl JMed 2009; 361: 2019-2032
4. Kliger AS, Fishbane S, Finkelstein FO. Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment. Clin J Am Soc Nephrol 2012; 7: 354-357
5. Coyne DW, Kapoian T, Suki Wet al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-984
6. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989; 35: 134-148
7. Hertig A, Ferrer-Marin F. Correction of anaemia on dialysis: did we forget physiology?. Nephrol Dial Transplant 2011; 26: 1120-1122
8. Sargent JA, Acchiardo SR. Iron requirements in hemodialysis. Blood Purif 2004; 22: 112-123
9. Ackrell BA, Maguire JJ, Dallman PR et al. Effect of iron deficiency on succinate- and NADH-ubiquinone oxidoreductases in skeletal muscle mitochondria. J Biol Chem 1984; 259: 10053-10059
10. McLane JA, Fell RD, McKay RH et al. Physiological and biochemical effects of iron deficiency on rat skeletal muscle. Am J Physiol 1981; 241: C47-C54
11. Krayenbuehl PA, Battegay E, Breymann C et al. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011; 118: 3222-3227
12. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093
13. Tomosugi N, Kawabata H, Wakatabe R et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood 2006; 108: 1381-1387
14. Ashby DR, Gale DP, Busbridge M et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009; 75: 976-981
15. Zaritsky J, Young B, Wang HJ et al. Hepcidin-A potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1051-1056
16. Weiss G, Theurl I, Eder S et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest 2009; 39: 883-890
17. Babitt JL, Lin HY. Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 2010; 55: 726-741
18. Ple H, Maltais M, Corduan A et al. Alteration of the platelet transcriptome in chronic kidney disease. Thromb Haemost 2012; 108: 605-615
19. Kadikoylu G, Yavasoglu I, Bolaman Z et al. Platelet parameters in women with iron deficiency anemia. J Natl Med Assoc 2006; 98: 398-402
20. Gurbel PA. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Rev Cardiovasc Med 2006; 7(Suppl 4): S20-S28
21. Aljaroudi WA, Halabi AR, Harrington RA. Platelet inhibitor therapy for patients with cardiovascular disease: looking toward the future. Curr Hematol Rep 2005; 4: 397-404
22. Streja E, Kovesdy CP, Greenland S et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52: 727-736
23. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000
24. Kurekci AE, Atay AA, Sarici SU et al. Effect of iron therapy on the whole blood platelet aggregation in infants with iron deficiency anemia. Thromb Res 2000; 97: 281-285
25. Dahl NV, Henry DH, Coyne DW. Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?. Semin Dial 2008; 21: 210-211
26. Milman N. Iron therapy in patients undergoing maintenance hemodialysis. Acta Med Scand 1976; 200: 315-319
27. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78
28. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-Alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
29. Freburger JK, Ng LJ, Bradbury BD et al. Changing patterns of anemia management in US hemodialysis patients. Am J Med 2012; 125: 906-914e909
30. Rozen-Zvi B, Gafter-Gvili A, Paul M et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-Analysis. Am J Kidney Dis 2008; 52: 897-906
31. Provenzano R, Schiller B, Rao M et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 386-393
32. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3: 1-150
33. Guyatt GH, Oxman AD, Kunz R et al. Going from evidence to recommendations. BMJ 2008; 336(7652): 1049-1051
34. Canavese C, Bergamo D, Ciccone G et al. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004; 65: 1091-1098
35. Ghoti H, Rachmilewitz EA, Simon-Lopez R et al. Evidence for tissue iron overload in long-Term hemodialysis patients and the impact of withdrawing parenteral iron. Eur J Haematol 2012; 89: 87-93
36. Rostoker G, Griuncelli M, Loridon C et al. Hemodialysis-Associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med 2012; 125: 991-999 e991
37. Vaya A, Hernandez JL, Zorio E et al. Association between red blood cell distribution width and the risk of future cardiovascular events. Clin Hemorheol Microcirc 2012; 50: 221-225
38. Brookhart MA, Freburger JK, Ellis AR et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol 2013; 24: 1151-1158
39. Rhee CM, Kalantar-Zadeh K. Is iron maintenance therapy better than load and hold?. J Am Soc Nephrol 2013; 24: 1028-1031
40. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 3505-3516
41. Singh AK, Coyne DW, Shapiro W et al. Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation. Kidney Int 2007; 71: 1163-1171
42. Ford BA, Coyne DW, Eby CS et al. Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int 2009; 75: 104-110
43. Cazzola M, Beguin Y. New tools for clinical evaluation of erythron function in man. Br J Haematol 1992; 80: 278-284
44. Skikne BS, Flowers CH, Cook JD. Serum transferrin receptor: a quantitative measure of tissue iron deficiency. Blood 1990; 75: 1870-1876
45. Ruzik S, Beguin Y. Serum soluble transferrin receptor concentration is an accurate estimate of the mass of tissue receptors. Exp Hematol 2001; 29: 677-685
46. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996; 1275: 161-203
47. Herbert V, Jayatilleke E, Shaw S et al. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells 1997; 15: 291-296
48. Yamanishi H, Iyama S, Yamaguchi Y et al. Relation between iron content of serum ferritin and clinical status factors extracted by factor analysis in patients with hyperferritinemia. Clin Biochem 2002; 35: 523-529
49. Spada PL, Rossi C, Alimonti A et al. Ferritin iron content in haemodialysis patients: comparison with septic and hemochromatosis patients. Clin Biochem 2008; 41: 997-1001
50. von Bonsdorff L, Lindeberg E, Sahlstedt L et al. Bleomycin-detectable iron assay for non-Transferrin-bound iron in hematologic malignancies. Clin Chem 2002; 48: 307-314
51. Piga A, Longo F, Duca L et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am J Hematol 2009; 84: 29-33
52. Taher A, Musallam KM, El Rassi F et al. Levels of non-Transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol 2009; 146: 569-572
53. Pootrakul P, Breuer W, Sametband M et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded betathalassemia/HbE patients treated with an oral chelator. Blood 2004; 104: 1504-1510
54. Scheiber-Mojdehkar B, Lutzky B, Schaufler R et al. Non-Transferrinbound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J Am Soc Nephrol 2004; 15: 1648-1655
55. Cabantchik ZI, Breuer W, Zanninelli G et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277-287
56. Jacobs A. Low molecular weight intracellular iron transport compounds. Blood 1977; 50: 433-439
57. Prus E, Fibach E. The labile iron pool in human erythroid cells. Br J Haematol 2008; 142: 301-307
58. Ghoti H, Amer J, Winder A et al. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 2007; 79: 463-467
59. Ghoti H, Fibach E, Merkel D et al. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes. Haematologica 2010; 95: 1433-1434
60. Prus E, Fibach E. Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytometry A 2008; 73: 22-27
61. Van der Putten K, Jie KE, Van Den Broek D et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail 2010; 12: 943-950
62. Kato A, Tsuji T, Luo J et al. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol 2008; 28: 115-121
63. Tessitore N, Girelli D, Campostrini N et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant 2010; 25: 3996-4002
64. Malyszko J, Malyszko JS, Levin-Iaina N et al. Is hemojuvelin a possible new player in iron metabolism in hemodialysis patients?. Int Urol Nephrol 2012; 44: 1805-1811
65. Sun CC, Vaja V, Chen S et al. A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats. Nephrol Dial Transplant 2013; 28: 1733-1743
66. Wagner M, Ashby D. Hepcidin-A well-known iron biomarker with prognostic implications in chronic kidney disease. Nephrol Dial Transplant 2013; 28: 2936-2939
67. Van der Weerd NC, Grooteman MP, Bots ML et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant 2013; 28: 3062-3071
68. Jensen PD, Jensen FT, Christensen T et al. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 2003; 101: 91-96
69. Angelucci E, Baronciani D, Lucarelli G et al. Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies. Br J Haematol 1995; 89: 757-761
70. Telfer PT, Prestcott E, Holden S et al. Hepatic iron concentration combined with long-Term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971-977
71. Agarwal MB. Advances in management of thalassemia. Indian Pediatr 2004; 41: 989-992
72. Voskaridou E, Douskou M, Terpos E et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. Br J Haematol 2004; 126: 736-742
73. Ghoti H, Fibach E, Westerman M et al. Increased serum hepcidin levels during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndrome. Br J Haematol 2011; 153: 118-120
74. Ferrari P, Kulkarni H, Dheda S et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 77-83
75. Anderson LJ, Holden S, Davis B et al. Cardiovascular T2-star (T2.∗) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-2179
76. Westwood M, Anderson LJ, Firmin DN et al. A single breath-hold multiecho T2.∗ cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003; 18: 33-39
77. Pepe A, Positano V, SantarelliMF et al.Multislice multiecho T2.∗ cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. JMagn Reson Imaging 2006; 23: 662-668
78. Positano V, Pepe A, Santarelli MF et al. Standardized T2.∗ map of normal human heart in vivo to correct T2.∗ segmental artefacts. NMR Biomed 2007; 20: 578-590
79. Nielsen P, Engelhardt R, Duerken M et al. Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. Transfus Sci 2000; 23: 257-258
80. Kletzmayr J, Horl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 2002; 17(Suppl 2): 25-29
81. Drueke TB, Massy ZA. Intravenous iron: how much is too much?. J Am Soc Nephrol 2005; 16: 2833-2835
82. Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193
83. Hershko CM, Link GM, Konijn AM et al. Iron chelation therapy. Curr Hematol Rep 2005; 4: 110-116
84. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci 1998; 850: 191-201
85. Rund D, Rachmilewitz E. Beta-Thalassemia. N Engl J Med 2005; 353: 1135-1146
86. Hershko C, Graham G, Bates GW et al. Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40: 255-263
87. Hebbel RP. Auto-oxidation and a membrane-Associated 'Fenton reagent': a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol 1985; 14: 129-140
88. Le Lan C, Loreal O, Cohen T et al. Redox active plasma iron in C282Y/C282Y hemochromatosis. Blood 2005; 105: 4527-4531
89. Gupta A, Zhuo J, Zha J et al. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol 2010; 11: 16
90. Deicher R, Ziai F, Cohen G et al. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003; 64: 728-736
91. Patruta SI, Edlinger R, Sunder-Plassmann G et al. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9: 655-663
92. GuoD, Jaber BL, Lee S et al. Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 2002; 58: 134-142
93. Zager RA. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol 2006; 1(Suppl 1): S24-S31
94. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 2004; 65: 1802-1809
95. Zoccali C. Endothelial dysfunction and the kidney: emerging risk factors for renal insufficiency and cardiovascular outcomes in essential hypertension. J Am Soc Nephrol 2006; 17(4 Suppl 2): S61-S63
96. Reis KA, Guz G, Ozdemir H et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 2005; 46: 255-264
97. Zager RA. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Kidney Int 2005; 68: 1533-1542
98. Weiss G, Meusburger E, Radacher G et al. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003; 64: 572-578
99. Boelaert JR, Daneels RF, Schurgers ML et al. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990; 5: 130-134
100. Bansal A, Sandhu G, Gupta I et al. Effect of aggressively driven intravenous iron therapy on infectious complications in end-stage renal disease patients on maintenance hemodialysis. Am J Ther 2012 [Epub ahead of print]
101. Linton TK, Pacheco MA, McIntyre DO et al. Development of bioassessment-based benchmarks for iron. Environ Toxicol Chem 2007; 26: 1291-1298
102. Beshara S, Lundqvist H, Sundin J et al. Kinetic analysis of 52Fe-labelled iron(III) hydroxide-sucrose complex following bolus administration using positron emission tomography. Br J Haematol 1999; 104: 288-295
103. Gokal R, Weatherall DJ, Bunch C. Iron induced increase in red cell size in haemodialysis patients. Q J Med 1979; 48: 393-401
104. Boll IT. A quantitative kinetic model of human erythropoiesis. Hamatol Bluttransfus 1972; 10: 9-12
105. Franzone PC, Paganuzzi A, Stefanelli M. A mathematical model of iron metabolism. J Math Biol 1982; 15: 173-201
106. Stefanelli M, Bentley DP, Cavill I et al. Quantitation of reticuloendothelial iron kinetics in humans. Am J Physiol 1984; 247(5 Pt 2): R842-R849
107. Nichols B, Shrestha RP, Horowitz J et al. Simplification of an erythropoiesis model for design of anemia management protocols in end stage renal disease. Conf Proc IEEE Eng Med Biol Soc 2011; 2011: 83-86
108. Chait Y, Horowitz J, Nichols B et al. Control-relevant erythropoiesis modeling in end-stage renal disease. IEEE Trans Biomed Eng 2014; 61: 658-664
109. Ljung L. System Identification: Theory for the User. Prentice-Hall, Placed Published, 1987.
110. Brier ME, Gaweda AE, Dailey A et al. Randomized trial of model predictive control for improved anemia management. Clin J Am Soc Nephrol 2010; 5: 814-820
111. Gaweda AE, Aronoff GR, Jacobs AA et al. Individualized Anemia Management Reduces Hemoglobin Variability in Hemodialysis Patients. J Am Soc Nephrol 2014; 25: 159-166
112. Gaweda AE, Jacobs AA, Aronoff GR et al. Model predictive control of erythropoietin administration in the anemia of ESRD. Am J Kidney Dis 2008; 51: 71-79
113. Gaweda AE, Aronoff GR, Jacobs AA et al. Individualized anemia management reduces hemoglobin variability in hemodialysis patients. J Am Soc Nephrol 2014; 25: 159-166